Postlicensure safety evaluation of human papilloma virus vaccines

International Journal of Risk and Safety in Medicine

Volumn 23, Issue 2, 2011, Pages 103-112

  Labadie, Jerry ^a  

^a UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ABDOMINAL PAIN; ALLERGIC REACTION; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; BACKACHE; BELL PALSY; BRONCHOSPASM; CONVULSION; DATA BASE; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ERYTHEMA; FATIGUE; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HEMATURIA; HUMAN; HYPERSENSITIVITY REACTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNIZATION; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PARESTHESIA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LEG PAIN; LICENSING; LUNG EMBOLISM; LYMPHADENOPATHY; MALAISE; MENSTRUATION DISORDER; MIGRAINE; MOTOR NEURON DISEASE; MYALGIA; MYELITIS; NAUSEA; NETHERLANDS; OUTCOME ASSESSMENT; PANCREATITIS; PRURITUS; RASH; SYNCOPE; TONIC CLONIC SEIZURE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VENOUS THROMBOEMBOLISM; VIRUS MENINGITIS; VOMITING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; ALPHAPAPILLOMAVIRUS; CONSUMER PRODUCT SAFETY; DATABASES, FACTUAL; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK ASSESSMENT;

EID: 80052058858     PISSN: 09246479     EISSN: 18786847     Source Type: Journal    
DOI: 10.3233/JRS-2011-0529     Document Type: Article

References (22)

1. H. Trottier and E.L. Franco, The epidemiology of genital human papillomavirus infection, Vaccine 24(1) (30 Mar 2006), S1-S15.
2. J.G. Baseman and L.A. Koutsky, The epidemiology of human papillomavirus infections, J Clin Virol 32(1) (Mar 2005), S16-S24.
3. S.K. Kjaer, A.J. van den Brule, G. Paull, E.I. Svare, M.E. Sherman, B.L. Thomsen, et al., Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population based prospective follow up study, BMJ 325(7364) (Sep 2002), 14, 572.
4. K.L. Wallin, F. Wiklund, T. Angstrom, F. Bergman, U. Stendahl, G. Wadell, et al., Type-specific persistence of human papillomavirusDNAbefore the development of invasive cervical cancer, N Engl J Med 341(22) (25 Nov 1999), 1633-1638.
5. N.F. Schlecht, S. Kulaga, J. Robitaille, S. Ferreira, M. Santos, R.A. Miyamura, et al., Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia, JAMA 286(24) (26 Dec 2001), 3106-3114.
6. B.A. Slade, L. Leidel, C.Vellozzi, E.J.Woo,W. Hua, A. Sutherland, et al., Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine, JAMA 302(7) (19 Aug 2009), 750-757.
7. T.M. van 't Klooster, J.M. Kemmeren, P.E. Vermeer-de Bondt, B. Oostvogels, T.A.J. PHaff, H.E. de Melker, et al., Human papillomavirus vaccination catch-up campaign in 2009 for girls born in 1993 to 1996 in the Netherlands RIVM Report 210012001/2011. Available from: Http://www.rivm.nl/ bibliotheek/rapporten/210012001.html.
8. Summary of product characteristics of Cervarix®. Available from: Http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000721/WC500024632.pdf
9. L. Rambout, L. Hopkins, B. Hutton and D. Fergusson, Prophylactic vaccination against human papillomavirus infection and disease in women: A systematic review of randomized controlled trials, CMAJ 177(5) (28 Aug 2007), 469-479.
10. T.F. Schwarz, AS04-adjuvanted human papillomavirus-16/18 vaccination: Recent advances in cervical cancer prevention, Expert Rev Vaccines 7(10) (Dec 2008), 1465-1473.
11. J. Paavonen, P. Naud, J. Salmerón, C.M. Wheeler, S.N. Chow, D. Apter, et al.; HPV PATRICIA Study Group, M. Greenacre Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomized study in young women, Lancet 374(9686) (25 July 2009), 301-314.
12. B. Romanowski, P.C. de Borba, P.S. Naud, C.M. Roteli-Martins, N.S. de Carvalho, J.C. Teixeira, et al.; Glaxo SmithKline Vaccine HPV-007 Study Group, Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine: Analysis of a randomized placebo-controlled trial up to 6.4 years, Lancet 374(9706) (12 Dec 2009), 1975-1985.
13. D. Descamps, K. Hardt, B. Spiessens, P. Izurieta, T. Verstraeten, T. Breuer, et al., Safety of human papillomavirus (HPV) -16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials, Hum Vaccine 5 (2009), 332-340.
14. Summary of product characteristics of Gardasil®. Available from: Http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000703/WC500021142.pdf (accessed 12 March 2011).
15. K.S. Reisinger, S.L. Block, E. Lazcano-Ponce, R. Samakoses, M.T. Esser, J. Erick, et al., Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16 and 18 L1 virus-like particle vaccine in preadolescents and adolescents: A randomized controlled trial, Pediatr Infect Dis J 26 (2007), 201-209.
16. N. Munoz, R. Manalastas Jr, P. Pitisuttithum, D. Tresukosol, J. Monsonego, K. Ault, et al., Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial, Lancet 373(9679) (2009), 1949-1957.
17. S.L. Block, D.R. Brown, A. Chatterjee, M.A. Gold, H.L. Sings and A. Meibohm, et al., Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine, Pediatr Infect Dis J 29(2) (2010), 95-101.
18. I.R. Edwards and S. Olsson, The WHO international drug mon itoring programme, In: Side Effects of Drugs Annual 25, J.K. Aronson, ed., Elsevier Science B.V., Amsterdam, 2002, 589-598.
19. M. Lindquist, VigiBase, the WHO global ICSR database system: Basic facts, Drug Inf J 42(5) (2008), 409-419.
20. C.A. Siegrist, E.M. Lewis, J. Eskola, S.J. Evans and S.B. Black, Human papilloma virus immunization in adolescent and young adults: A cohort study to illustrate what events might be mistaken for adverse reactions, Pediatr Infect Dis J 26(11) (Nov 2007), 979-984.
21. T. Callréus, H. Svanström, N.M. Nielsen, S. Poulsen, P. Valentiner-Branth and A. Hviid, Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events, Vaccine 27 (2009), 2954-2958.
22. C.A. Siegrist, Autoimmune diseases after adolescent or adult immunization: What should we expect? CMAJ 177(11) (20 Nov 2007), 1352-1354.